Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 28:1:3.
doi: 10.1186/s41927-017-0001-8. eCollection 2017.

Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets

Affiliations
Review

Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets

Alessia Alunno et al. BMC Rheumatol. .

Abstract

In recent years, the landscape of pro- and anti-inflammatory cytokines has rapidly expanded with the identification of new members proven to be involved at different extent in the pathogenesis of chronic immune mediated inflammatory diseases including rheumatoid arthritis (RA). The advance of our understanding of mediators involved in the pathogenesis of RA and in consequence, the development of novel targeted therapies is necessary to provide patients not responding to currently available strategies with novel compounds. The aim of this review article is to provide an overview on recently identified cytokines, emphasizing their pathogenic role and therapeutic potential in RA. A systematic literature review was performed to retrieve articles related to every cytokine discussed in the review. In some cases, evidence from animal models and RA patients is already consistent to move forward into drug development. In others, conflicting observation and the paucity of data require further investigations.Forty years after the discovery of IL-1, the landscape of cytokines is continuously expanding with increasing possibilities to develop novel therapeutic strategies in RA.

PubMed Disclaimer

Conflict of interest statement

AA (Assistant Professor), FC (Consultant and Postdoctoral Researcher), RGi (Full Professor), RGe (Full Professor) have a consolidated experience in the field of chronic inflammatory rheumatic diseases with particular interest in the immune-pathogenesis of these disorders.Not applicableNot applicableAA and FC are members of the Editorial Board of BMC Rheumatology. The other authors have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

Cited by

References

    1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi: 10.1016/S0140-6736(16)30173-8. - DOI - PubMed
    1. Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A. One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(4):551–558. - PubMed
    1. Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity. 2014;47(2):77–94. doi: 10.3109/08916934.2013.873413. - DOI - PubMed
    1. Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford) 2012;51:2252–2261. doi: 10.1093/rheumatology/kes217. - DOI - PubMed
    1. Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediat Inflamm. 2014;2014:545493. - PMC - PubMed

LinkOut - more resources